A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Part of paid clinical trials in San Francisco, California.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07492680
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986504 — DRUG
    Specified dose on specified days
  • Daraxonrasib — DRUG
    Specified dose on specified days
  • Nivolumab + Relatlimab FDC — DRUG
    Specified dose on specified days
  • Temozolomide — DRUG
    Specified dose on specified days
  • Pumitamig — DRUG
    Specified dose on specified days
  • Pemetrexed — DRUG
    Specified dose on specified days
  • Carboplatin — DRUG
    Specified dose on specified days
  • Nab-paclitaxel — DRUG
    Specified dose on specified days
  • Gemcitabine — DRUG
    Specified dose on specified days
  • Paclitaxel — DRUG
    Specified dose on specified days

Study Details

This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BMS-986504 alone and in combination regimens.

Key Dates

First listed
Mar 25, 2026
Start date
Jul 27, 2026
Status verified
Jul 2026
Primary completion
Aug 15, 2028
Completion
May 20, 2032

Study Design

Enrollment
260 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1a
    BMS-986504
  • Experimental: Part 1b
    BMS-986504
  • Experimental: Part 2: Cohort 1
    BMS-986504 + Pumitamig + Chemotherapy
  • Experimental: Part 2: Cohort 2a
    BMS-986504 + Daraxonrasib
  • Experimental: Part 2: Cohort 2b
    BMS-986504 + Daraxonrasib
  • Experimental: Part 2: Cohort 2c
    BMS-986504 + Daraxonrasib + Chemotherapy
  • Experimental: Part 2: Cohort 3
    BMS-986504 + Nivolumab + Relatlimab FDC
  • Experimental: Part 2: Cohort 4
    BMS-986504 + Temozolomide + Radiotherapy

Primary Outcome Measure

Part 1: Number of participants who achieve Objective Response (OR) [ Time Frame: Up to approximately 2 years ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (16)

FacilityCityStateZIPSite coordinators
Local Institution - 0096San FranciscoCalifornia94158
Site 0096
Local Institution - 0182AuroraColorado80045
Site 0182
Local Institution - 0178AtlantaGeorgia30322
Site 0178
Johns Hopkins HospitalBaltimoreMaryland21287
Kristen Marrone, Site 0143
410-550-1711
Local Institution - 0124BostonMassachusetts02114
Site 0124
Local Institution - 0119Ann ArborMichigan48109-0922
Site 0119
Local Institution - 0129RochesterMinnesota55905
Site 0129
Local Institution - 0174RochesterMinnesota55905
Site 0174
Local Institution - 0181RochesterMinnesota55905
Site 0181
Local Institution - 0142BuffaloNew York14263
Site 0142
Local Institution - 0139New YorkNew York10065
Site 0139
Local Institution - 0170New YorkNew York10016
Site 0170
Local Institution - 0100DurhamNorth Carolina27705
Site 0100
Local Institution - 0085HoustonTexas77030
Site 0085
Local Institution - 0086SeattleWashington98109
Site 0086
Local Institution - 0134MadisonWisconsin53792
Site 0134

Find similar trials in San Francisco, CA

By research site
Local Institution - 0096· San Francisco, CALocal Institution - 0182· Aurora, COLocal Institution - 0178· Atlanta, GAJohns Hopkins Hospital· Baltimore, MDLocal Institution - 0124· Boston, MALocal Institution - 0119· Ann Arbor, MI

Related Studies